ArQule, Inc.
19 Presidential Way
Woburn
Massachusetts
01801
United States
Tel: 781-994-0300
Fax: 781-376-6019
Website: http://www.arqule.com/
Email: Info@arqule.com
363 articles about ArQule, Inc.
-
ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
7/13/2018
ArQule, Inc. announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,650,000 shares at the public offering price of $5.50 per share.
-
ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock
7/11/2018
The offering is expected to close on or about July 13, 2018, subject to satisfaction of customary closing conditions.
-
ArQule Announces Commencement of Proposed Public Offering of Common Stock
7/10/2018
ArQule, Inc. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.
-
Six biotechs will end the month of June as new additions to the Russell Indexes. Approximately $9 trillion in assets are benchmarked against Russell U.S. Indexes, which are reconstituted annually.
-
ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531
6/15/2018
Preliminary data from Phase 1 dose escalation trial highlights the potential of ARQ 531 to become a new therapeutic option for patients with B-cell malignancies
-
ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018
6/14/2018
ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at The JMP Securities Life Sciences Conference.
-
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)
6/7/2018
ArQule, Inc. today announced clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study will be presented at the EHA Congress in Stockholm, Sweden.
-
ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018
5/31/2018
ArQule, Inc. announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the Jefferies 2018 Healthcare Conference.
-
ArQule Strengthens Executive Team with Two Key Appointments
5/24/2018
Newly Created Positions of Senior Vice President, Corporate Strategy, Communication & Finance and Senior Vice President, Program Management and Product Planning
-
ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China
4/17/2018
ArQule eligible to receive up to $336 million including upfront, regulatory and commercial milestone payments
-
ArQule Reports Fourth Quarter and Full Year 2017 Financial Results
3/5/2018
Conference call scheduled today at 9:00 a.m. ET
-
Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China
2/7/2018
Roivant Sciences and ArQule today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater China.
-
ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma
11/21/2017
The trial is planned to enroll up to 100 iCCA patients and provides an opportunity for a conditional approval as part of a fast-to-market strategy.
-
ArQule Reports Third Quarter 2017 Financial Results
11/9/2017
For the quarter ended September 30, 2017, the Company reported a net loss of $6,666,000 or $0.09 per share, compared with a net loss of $5,817,000 or $0.08 per share, for the third quarter of 2016.
-
ArQule Announces $9.5 Million Private Placement of Preferred Stock
11/8/2017
The Pontifax Group pursuant to which the Company raised gross proceeds of $9.5 million through the sale of approximately 8,370 shares of series A convertible preferred stock (Series A Preferred) and warrants covering 2,260 shares of Series A Preferred (Warrants).
-
FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome
11/1/2017
Miransertib is an orally available, selective pan-AKT inhibitor.
-
ArQule to Report Third Quarter 2017 Financial Results on November 9, 2017
10/26/2017
ArQule, Inc. today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017.
-
ArQule Announces $15.7 Million Private Placement of Common Stock
10/16/2017
ArQule, Inc. today announced the closing of a private placement with certain institutional investors, with leading participation by BVF Partners L.P., pursuant to which the Company raised gross proceeds of approximately $15.7 million through the sale of 13,938,651 shares of common stock and 3,123,674 warrants.
-
ArQule Reports Second Quarter 2017 Financial Results
8/4/2017
-
ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017
7/21/2017